Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type, By Technology (Tandem Mass Spectrometry, Immunoassay), By End-use And Segment Forecasts, 2018 - 2024

Industry Insights

The global endocrine testing market size was valued at USD 7.04 billion in 2016 and is expected to witness a CAGR of 8.0% over the forecast period. Growing incidences of endocrine disorders such as hyperthyroidism and adrenal insufficiency are predicted to boost the demand for endocrine testing.

The growing diabetic, geriatric, and obese population worldwide is expected to promote market growth. Furthermore, growing healthcare awareness among individuals coupled with increasing government support is expected to increase the diagnosis at an early, thereby contributing to the growth of the endocrine testing market.

The growing prevalence of lifestyle diseases is also expected to contribute to the demand for the endocrine test, thereby contributing to the market growth. Rising cases for diseases such as hypothyroidism and hyperthyroidism is also expected to propel the demand for advanced endocrine testing technologies.

Advancement in technologies such as introduction of easy-to-operate test kits facilitated the penetration of home-based diagnosis, which is user-friendly and cost-effective. Moreover, the target of this market is the geriatric population owing to its increased susceptibility to chronic diseases and the high risk of developing complications at an older age, which makes continuous monitoring essential in these elderly patients.

Owing to increasing health awareness around the world, there has been advancement in home health care along with easy operating home diagnostic kits which are cost-effective and designed with precision. Many new mass spectrometric technologies have been introduced which deliver accurate results in less time and they are highly sensitive.

Mass Spectrometry is now coupled with liquid chromatography for more precision. Telehealth services have also been introduced by some commercial laboratories and stand-alone clinics. Fully automated systems have been designed for faster diagnosis and increased sample size testing.

The rising number of healthcare settings, especially in developing regions is fostering the growth of the endocrine testing market. For instance, in 2014, Saudi Arabia's government allocated USD 28 billion in health and development sectors. With the help of this grant, 17 new hospitals, and the expansion of 137 hospitals and primary health centers are anticipated. Similarly, in Qatar, the number of hospital beds is expected to rise from 4,980 in 2013 to 5,725 in 2018. These expansions are expected to create avenues for the therapeutic market.

Test Type Insights

Based on test type, the market is segmented into Estradiol (E2), Human Chorionic Gonadotropin (hCG), Follicle Stimulating (FSH), Dehydroepiandrosterone sulfate (DHEAS), Progesterone, Luteinizing Hormone (LH), testosterone, thyroid prolactin, Thyroid Stimulating Hormone (TSH), cortisol, insulin, and other tests such as gastrin, thymosin, and secretin tests.

Thyroid-stimulating hormone (TSH) test accounted for a lucrative share in 2016, This can be attributed to the increasing incidences of TSH-related disorders and the growing awareness regarding the correlation between variations in the thyroid hormones levels and cardiovascular disorders.

The insulin test is anticipated to witness the fastest growth over the forecast period. The substantial rise in the diabetic population and the growing awareness about diagnosis are anticipated to contribute towards the demand for insulin tests over the forecast period.

Technology Insights

Key technology segments include tandem mass spectrometry, immunoassay, monoclonal & polyclonal antibody technologies, sensors, clinical chemistry technologies, and others such as Liquid Chromatography with Mass Spectrometry (LC-MS).

The tandem mass spectrometry is expected to dominate the market during the forecast period. This can be attributed to growing use of tandem mass spectrometry in combination with liquid chromatography which helps in overcoming the challenges associated with traditional techniques used for endocrine testing.

Sensor Technology is expected to show the fastest growth among all the segments owing to growing use of biosensors in glucose monitoring for diabetes which is used on routine basis by the individuals to monitor their blood sugar level in undiluted blood samples.

End-use Insights

The market based on end-use is segmented into hospitals, commercial laboratories, ambulatory care centers, and other healthcare settings. The hospital segment accounted for the largest share in 2016 and is expected to dominate the market during the forecast period.

The commercial laboratory segment is expected to witness the fastest growth owing to availability of advanced infrastructure coupled with skilled personnel.

Regional Insights

Geographically, the endocrine testing market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. The presence of well-developed primary, secondary, tertiary care hospitals supported the growth in the North American region. Moreover, a well-developed reimbursement network, favorable government funding, and increasing health awareness facilitated the usage of advanced techniques for endocrine testing.

Asia-Pacific endocrine testing market is expected to witness a lucrative CAGR of 9.1% over the forecast period. Key factors attributed to market growth include growing R&D expenditure by the government and private agencies in order to improve diagnostic and therapeutic areas in the region. Economic development in countries such as India, China, and Japan coupled with favorable government initiatives pertaining to the development of healthcare infrastructure and reimbursement policies are further expected to fuel market growth.

Endocrine Testing Market Share Insights

The major share in endocrine testing market share is held by companies such as Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies, bioMerieux SA, Bio Rad Laboratories, DiaSorin, Hoffmann-La Roche Ltd., LabCorp, and Quest Diagnostics.

The players are actively involved in launching technologically advanced products and initiate collaborative developments to sustain themselves in the competition. For instance, LabCorp offers all-embracing solutions on clinical trials pertaining to diabetes and all other hormonal diseases. In addition, the company also provides liquid chromatography in combination with mass spectrometry to yield specific results even with minimal amounts of the hormonal sample.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global endocrine testing market report on the basis of test type, technology, end use, and region

• Test Type Outlook (Revenue, USD Million, 2013 - 2024)

  • Estradiol

  • FSH

  • hCG

  • LH

  • DHEAS

  • Progesterone

  • Testosterone

  • TSH

  • Prolactin

  • Cortisol

  • Insulin

  • Others

• Technology Outlook (Revenue, USD Million, 2013 - 2024)

  • Tandem Mass Spectrometry

  • Immunoassay

  • Monoclonal & Polyclonal antibody technologies

  • Sensor technology

  • Clinical chemistry

  • Others

• End-use Outlook (Revenue, USD Million, 2013 - 2024)

  • Hospital

  • Commercial Laboratory

  • Ambulatory Care Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2013 - 2024)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa